| Combination epigenetic therapy has efficacy in patients with refractory advanced non–small cell lung cancer RA Juergens, J Wrangle, FP Vendetti, SC Murphy, M Zhao, B Coleman, ... Cancer discovery 1 (7), 598-607, 2011 | 732 | 2011 |
| Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms SD Gore, S Baylin, E Sugar, H Carraway, CB Miller, M Carducci, M Grever, ... Cancer research 66 (12), 6361-6369, 2006 | 598 | 2006 |
| Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation F Ravandi, ML Alattar, MR Grunwald, MA Rudek, T Rajkhowa, MA Richie, ... Blood, The Journal of the American Society of Hematology 121 (23), 4655-4662, 2013 | 446 | 2013 |
| Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance KJ Gotink, HJ Broxterman, M Labots, RR De Haas, H Dekker, ... Clinical Cancer Research 17 (23), 7337-7346, 2011 | 349 | 2011 |
| A targeting modality for destruction of RNA polymerase I that possesses anticancer activity K Peltonen, L Colis, H Liu, R Trivedi, MS Moubarek, HM Moore, B Bai, ... Cancer cell 25 (1), 77-90, 2014 | 315 | 2014 |
| Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research HIV working group TS Uldrick, G Ison, MA Rudek, A Noy, K Schwartz, S Bruinooge, ... Journal of clinical oncology: official journal of the American Society of …, 2017 | 314 | 2017 |
| The rising challenge of non–AIDS-defining cancers in HIV-infected patients JF Deeken, A Tjen-A-Looi, MA Rudek, C Okuliar, M Young, RF Little, ... Clinical infectious diseases 55 (9), 1228-1235, 2012 | 281 | 2012 |
| Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer S Bisht, M Mizuma, G Feldmann, NA Ottenhof, SM Hong, D Pramanik, ... Molecular cancer therapeutics 9 (8), 2255-2264, 2010 | 264 | 2010 |
| Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia YB Chen, S Li, AA Lane, C Connolly, C Del Rio, B Valles, M Curtis, ... Biology of Blood and Marrow Transplantation 20 (12), 2042-2048, 2014 | 254 | 2014 |
| Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration‐resistant prostate cancer ES Antonarakis, EI Heath, DC Smith, D Rathkopf, AL Blackford, DC Danila, ... The oncologist 18 (2), 163-173, 2013 | 208 | 2013 |
| Targeting DDX 3 with a small molecule inhibitor for lung cancer therapy GM Bol, F Vesuna, M Xie, J Zeng, K Aziz, N Gandhi, A Levine, A Irving, ... EMBO molecular medicine 7 (5), 648-669, 2015 | 201 | 2015 |
| Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer MA Rudek, WD Figg, V Dyer, W Dahut, ML Turner, SM Steinberg, ... Journal of Clinical Oncology 19 (2), 584-592, 2001 | 198 | 2001 |
| Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters S Hu, Z Chen, R Franke, S Orwick, M Zhao, MA Rudek, A Sparreboom, ... Clinical Cancer Research 15 (19), 6062-6069, 2009 | 197 | 2009 |
| Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study M Cianfrocca, TP Cooley, JY Lee, MA Rudek, DT Scadden, L Ratner, ... Journal of clinical oncology 20 (1), 153-159, 2002 | 197 | 2002 |
| Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors JH Kalin, M Wu, AV Gomez, Y Song, J Das, D Hayward, N Adejola, M Wu, ... Nature communications 9 (1), 53, 2018 | 196 | 2018 |
| Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study HJ Hammers, HM Verheul, B Salumbides, R Sharma, M Rudek, J Jaspers, ... Molecular cancer therapeutics 9 (6), 1525-1535, 2010 | 190 | 2010 |
| Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours R Pili, B Salumbides, M Zhao, S Altiok, D Qian, J Zwiebel, MA Carducci, ... British journal of cancer 106 (1), 77-84, 2012 | 177 | 2012 |
| Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan NPH Van Erp, SD Baker, M Zhao, MA Rudek, HJ Guchelaar, JWR Nortier, ... Clinical cancer research 11 (21), 7800-7806, 2005 | 173 | 2005 |
| A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer RK Anchoori, B Karanam, S Peng, JW Wang, R Jiang, T Tanno, ... Cancer cell 24 (6), 791-805, 2013 | 166 | 2013 |
| Use of antineoplastic agents in patients with cancer who have HIV/AIDS MA Rudek, C Flexner, RF Ambinder The lancet oncology 12 (9), 905-912, 2011 | 146 | 2011 |
Sharyn BakerThe Ohio State UniversityGeverifieerd e-mailadres voor osu.edu
